We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Nephron Voluntarily Recalls 2M Doses After FDA Inspection Finds Lack of Sterility
Nephron Voluntarily Recalls 2M Doses After FDA Inspection Finds Lack of Sterility
Nephron Pharmaceuticals of South Carolina has issued a voluntary recall of about 2 million doses of its medicines after an FDA inspection found a “lack of assurance of sterility” across 20 of the company’s mostly injectable medicines manufactured at its West Columbia, S.C., compounding facility.